Cellusion Director and Executive Appointments
Cellusion Inc. announced the appointment of members to its Board of Directors following approval at the 9th Ordinary General Meeting of Shareholders that took place today.
[Members of the Board of Directors]
Shin Hatou Representative Director, President, CEO (Reappointed)
Joji Hayashida Board Director, Executive Vice President, COO (Reappointed)
Takuya Kaneko Board Director, CFO (Newly appointed)
Tomokatsu Hongo Board Director (Reappointed)
Toru Seo Board Director (Reappointed)
Joyce Cheng Board Director (Reappointed)
Hiroaki Kobayashi Board Director (Reappointed)
Yoshiharu Asai Board Director (Reappointed)
[Audit & Supervisory Board Members]
Ikuo Mashimo Outside Corporate Auditor (Full-Time) (Not re-elected)
Tomotaka Goji Outside Corporate Auditor (Not re-elected)
Norihisa Kobayashi Outside Corporate Auditor (Not re-elected)
Hiromi Furushima Outside Corporate Auditor (Not re-elected)
[Executive Officer]
Shinobu Takemura (Newly appointed)
[About Takuya Kaneko]
After graduating from the University of Tokyo, Faculty of Law, Mr. Kaneko joined the Export-Import Bank of Japan (currently Japan Bank for International Cooperation). He received his LL.M. from Boston University School of Law. After that, he worked at Morgan Stanley Japan Securities Co., Ltd. (currently Mitsubishi UFJ Morgan Stanley Securities Co., Ltd.), where he worked in investment banking for over 16 years, and has experience in numerous fundraising, IPO, and M&A transactions also in the healthcare sector.
Mr. Kaneko joined Cellusion in 2022 as CFO and led the Series C financing, and was appointed as Executive Officer, CFO in 2023.
[About Shinobu Takemura]
After completing the first half of the doctor course in the Department of Materials Science and Chemical Engineering at Yokohama National University Graduate School, Ms. Takemura joined Hitachi Software Engineering Co., Ltd. (currently Hitachi Solutions, Ltd.) and was temporary transferred to Plant Genome Center Co., Ltd. and DNA Chip Research Inc. to engage in research work.
In 2006, she joined Oncolys BioPharma, Inc. where she worked as an IP specialist and has been involved in IP work ever since. After passing the patent attorney examination in 2010, she gained experience in IP work in the chemical and biotechnology fields at Oji Paper Co., Ltd. (currently Oji Holdings Corporation), followed by legal work as well as IP work at YAMASHIN-FILTER CORP.
Ms. Takemura joined Cellusion in 2022. In addition to her expertise in biotechnology, she is a specialist with the ability to formulate and implement IP strategies in line with management strategies.
Qualified as a Patent Attorney with Supplementary Note of Specific Infringement Lawsuit Counsel.
[About Cellusion]
Cellusion is a regenerative medicine startup originating from the Department of Ophthalmology, Keio University School of Medicine, with “Regenerating Human Potential” as its mission and “More Freedom and More Smiles to the World” as its vision. Based on patented technology such as its proprietary technique of efficiently producing corneal endothelial substitute cell from iPS cells, Cellusion is promoting R&D aimed at meeting medical needs from the perspective of “patient centricity” by leveraging cutting-edge regenerative medicine technology, including the lead program CLS001 that aims to meet the global corneal transplant demands.
Company: Cellusion Inc.
CEO: Shin Hatou, M.D., Ph.D.
Headquarters: Harumi Center bldg. 5th floor, 2-5-24 Harumi, Chuo, Tokyo 104-0053
Founded: January 2015
URL: https://cellusion.jp/en/
For further information: please ask us through the contact form on our website.
